Tempest Therapeutics Inc (NASDAQ: TPST) on Monday, soared 18.97% from the previous trading day, before settling in for the closing price of $0.71. Within the past 52 weeks, TPST’s price has moved between $0.70 and $6.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 29.53%. With a float of $39.62 million, this company’s outstanding shares have now reached $43.64 million.
Let’s determine the extent of company efficiency that accounts for 17 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Tempest Therapeutics Inc (TPST) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tempest Therapeutics Inc is 9.21%, while institutional ownership is 5.50%. The most recent insider transaction that took place on Aug 12 ’24, was worth 426,993. Before that another transaction happened on Aug 08 ’24, when Company’s 10% Owner sold 400,000 for $1.35, making the entire transaction worth $540,040. This insider now owns 597,940 shares in total.
Tempest Therapeutics Inc (TPST) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.53% per share during the next fiscal year.
Tempest Therapeutics Inc (NASDAQ: TPST) Trading Performance Indicators
Tempest Therapeutics Inc (TPST) is currently performing well based on its current performance indicators. A quick ratio of 1.69 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.54, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.04 in one year’s time.
Technical Analysis of Tempest Therapeutics Inc (TPST)
Looking closely at Tempest Therapeutics Inc (NASDAQ: TPST), its last 5-days average volume was 2.33 million, which is a jump from its year-to-date volume of 2.06 million. As of the previous 9 days, the stock’s Stochastic %D was 30.49%. Additionally, its Average True Range was 0.08.
During the past 100 days, Tempest Therapeutics Inc’s (TPST) raw stochastic average was set at 9.99%, which indicates a significant decrease from 57.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.72% in the past 14 days, which was lower than the 105.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9512, while its 200-day Moving Average is $2.1023. However, in the short run, Tempest Therapeutics Inc’s stock first resistance to watch stands at $0.8964. Second resistance stands at $0.9462. The third major resistance level sits at $1.0344. If the price goes on to break the first support level at $0.7584, it is likely to go to the next support level at $0.6702. Now, if the price goes above the second support level, the third support stands at $0.6204.
Tempest Therapeutics Inc (NASDAQ: TPST) Key Stats
Market capitalization of the company is 36.95 million based on 43,642K outstanding shares. Right now, sales total 0 K and income totals -29,490 K. The company made 0 K in profit during its latest quarter, and -10,560 K in sales during its previous quarter.
